New drugs for epilepsy

Current Opinion in Neurology

Volumn 11, Issue 2, 1998, Pages 141-148

  Sander, Josemir W A S ^a,b,c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

^c Epilepsy Research Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ANOREXIA; APLASTIC ANEMIA; ATAXIA; BEHAVIOR DISORDER; CHEMICAL TERATOGENESIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFUSION; DEPRESSION; DIPLOPIA; DRUG SAFETY; EPILEPSY; FATIGUE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LIVER FAILURE; NAUSEA; NEPHROLITHIASIS; RASH; REVIEW; SKIN ALLERGY; SPEECH DISORDER; TREMOR; VERTIGO; VOMITING;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; DRUG THERAPY; ELECTRIC STIMULATION THERAPY; EPILEPSY; HUMANS; VAGUS NERVE;

EID: 0031942097     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199804000-00011     Document Type: Review

References (86)

1. Walker MC, Sander JW. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996; 46:912-914.
2. Sander JW. The new antiepileptic drugs: their current role in the management of epilepsy. Eur J Neurol 1996; 3 (Suppl 3):15-20.
3. Sander JW. Some aspects of the prognosis of the epilepsies: a review. Epilepsia 1993; 34:1007-1016.
4. O'Donoghue MF, Sander JW. How rational is current antiepileptic drug treatment? Rev Neurol (Paris) 1997; 153 (Suppl 1):25-28.
5. Reynolds EH. Polytherapy revisited. Eur J Neurol 1996; 3 (Suppl 3):9-13.
6. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1996; 313:1169-1174. This is an interesting meta-analysis of all randomized placebo-controlled clinical trials of the tolerability and efficacy measured in terms of 50% seizure reduction of the new AEDs gabapentin, lamotrigine, tiagabine, topiramate. vigabatrin and zonisamide in patients with refractory partial epilepsy. No difference was established between the drugs.
7. Chadwick DW, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 1996; 37 (Suppl 6):S17-S22
8. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997; 38 (Suppl 1):S9-S17.
9. Perucca E. Principles of drug treatment. In: Shorvon SD, Dreifuss F, Fish D, Thomas D (editors): The treatment of epilepsy. Oxford: Blackwell; 1997. pp. 152-168.
10. Nashef L, Fish DR, Sander JW, Shorvon SD, Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre. J Neurol Neurosurg Psychiatry 1995; 58:462-464.
11. Leestma JE, Annegers JF, Brodie MJ, Brown S, Schraeder P, Siscovick D, et al. Sudden unexplained death in epilepsy: observations from a large clinical development program. Epilepsia 1997; 38:47-55. A study of the rate of sudden death in patients included in lamotrigine clinical trials is presented. Lamotrigine does not seem to influence this rate.
12. Nashef L, Brown S. Epilepsy and sudden death. Lancet 1996; 348:1324-1325.
13. Walker MC, Li LM, Sander JW. Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome. Br Med J 1996; 313:1184-1185. This paper outlines an audit of the long-term outcome in terms of seizure freedom and mortality of patients with chronic partial epilepsy recruited into early studies of the new AEDs vigabatrin and lamotrigine. These drugs had little impact in the long-term prognosis of these patients.
14. Patsalos PN, Sander JW. Newer antiepileptic drugs: towards an improved risk-benefit ratio. Drug Safety 1994; 11:37-67.
15. Chadwick D. New antiepileptic drugs. Q J Med 1994; 87:139-141.
16. Wilson EA, Brodie MJ. New antiepileptic drugs. Baillieres Clin Neurol 1996; 5:723-724.
17. Provinciali L, Bartolini M, Mari F, Del-Pesce M, Ceravolo MG. Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurol Scand 1996; 94:12-18.
18. Kalviainen R, Aikia M, Mervaala E, Saukkonen AM, Pitkanen A, Riekkinen PJ. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996; 25:291-297.
19. Brodie MJ, Pellock JM. Taming the brain storms: felbamate updated. Lancet 1995; 346:918-919.
20. Troost RJ, Van-Parys JA, Hooijkaas H, van-Joost T, Benner R, Prens EP. Allergy to carbamazepine: parallel in vivo and in vitro detection. Epilepsia 1996; 37:1093-1099.
21. Shorvon SD, Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia 1997; 38 (Suppl 1):S45-S51. A good review of the tolerability and safety profile of new AEDs is presented.
22. Rogvi-Hansen B, Gram L. Adverse effects of established and new antiepileptic drugs: an attempted comparison. Pharmacol Ther 1995; 68:425-434.
23. Guberman A, Vigabatrin. Can J Neurol Sci 1996; 23 (Suppl 4):S13-S17.
24. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42:531-543. A good review of the efficacy, tolerability and pharmacokinetics of all newly marketed AEDs is presented.
25. Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res 1997; 27:29-32.
26. Leppik I. Felbamate. Epilepsia 1995; 36 (Suppl 2):S66-S72.
27. O'Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46:1457-1459.
28. Bourgeois B. Felbamate. Semin Pediatr Neorol 1997; 4:3-8.
29. Knowles S, Shapiro L, Shear-NH Serious dermatologic reactions in children. Curr Opin Pediatr 1997; 9:388-395. This paper provides an interesting review of lamotrigine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.
30. Sachs B, Ronnau AC, von-Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997; 195:60-64.
31. Anon. Epilepsy drug exhibits fatal side effects. Nat Biotechnol 1997; 15:398.
32. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1996; 37 (Suppl 6):S34-S44. A good review is presented of the impact of the new AED on reproductive health.
33. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314:180-181. This is the first report of a potential chronic side-effect of a new AED.
34. Gram L. Pharmacokinetics of new antiepileptic drugs. Epilepsia 1996; 37 (Suppl 6):S12-S16.
35. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet 1996; 31:470-493.
36. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996; 31:29-46.
37. Walker MC, Sander JW. Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology 1997; 49:333-337. This is an interesting discussion of the role and shortcomings of meta-analysis of controlled trials of AEDs using 50% seizure reduction as the measure of efficacy. It is argued that new AED trials can determine appropriate use of AEDs but fail to determine their exact role in treating patients. The need for large multicenter studies in well defined populations with well characterized epilepsy syndromes and aetiologies, using seizure freedom as the primary measure of efficacy is emphasized.
38. Cockerell OC, Hart YM, Sander JWAS, Shorvon SD. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994; 18:249-260.
39. Malmgren K, Hedstrom A, Granqvist R, Malmgren H, Ben-Menachem-E. Cost analysis of epilepsy surgery and of vigabatrin treatment in patients with refractory partial epilepsy. Epilepsy Res 1996; 25:199-207.
40. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345:476-479. This comparative trial between an established AED, carbamazepine, and the new AED lamotrigine failed to show any difference in terms of efficacy.
41. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen P. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch-Neurol 1995; 52:989-996. This comparative trial between an established AED, carbamazepine, and the new AED vigabatrin suggests that carbamazepine is better in terms of rendering patients seizure free.
42. Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional crossover study. Epilepsy Res 1996; 25:257-262. This comparative trial between an established AED, carbamazepine, and the new AED vigabatrin failed to show any difference between the drugs in terms of efficacy.
43. Guerreiro MM, Vigonius U, Pohlmann H, de-Manreza ML, Fejerman N, Antoniuk SA, Moore A. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27:205-213. This comparative trial between an established AED, phenytoin, and the new AED oxcarbazepine failed to show any difference between the drugs in terms of efficacy.
44. Bill PA, Vigonius U, Pohlmann H, Guerreiro CA, Kochen S, Saffer D, Moore A. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27:195-204. Another comparative trial between an established AED, phenytoin, and the new AED oxcarbazepine failed to show any difference between the drugs in terms of efficacy.
45. Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, Moore A. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26:451-460. This comparative trial between an established AED, valproate, and the new AED oxcarbazepine failed to show any difference between the drugs in terms of efficacy.
46. French JA. What trials, which designs? Epilepsia. 1997; 38:263-265. An interesting comment is made on the design of clinical trials for AEDs.
47. Mignot G. Drug trials in epilepsy. Br Med J 1996; 313:1158.
48. Benbadis SR, Luders HO. Epileptic syndromes: an underutilized concept. Epilepsia 1996; 37:1029-1034.
49. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996; 61:433-443.
50. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 (Suppl 6):S4-S11.
51. Macdonald RL, Greenfield LJ. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol 1997; 10:121-128.
52. Li LM, Nashef L, Moriarty J, Duncan JS, Sander JW. Felbamate as add-on therapy. Eur Neurol 1996; 36:146-148.
53. Avanzini G, Canger R, Dalla-Bernardina B, Vigevano F. Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group. Epilepsy Res 1996; 25:249-255.
54. Bruni J. Gabapentin. Can J Neurol Sci 1996; 23 (4S):S3-S5.
55. •].
56. •] outline two trials that provide some support for the use of gabapentin as monotherapy in some patients with chronic partial epilepsy.
57. •].
58. •] outline two trials that show no effect of gabapentin in generalized seizures.
59. Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997; 62:372-376. This trial suggest that gabapentin has no measurable effect on cognition but that it produces sedation at high doses.
60. Boas J, Dam M, Friis ML, Kristensen O, Pedersen-B, Gallagher J. Controlled trial of lamotrigine for treatment-resistant partial seizures. Acta Neurol Scand 1996; 94:247-252.
61. Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992; 32:305-307.
62. Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome). Epilepsia 1997; 38:68-73.
63. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992; 11:147-150.
64. Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995; 67:351-384.
65. Eriksson AS, Hoppu K, Nergardh A, Boreus L. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996; 37:769-773.
66. Makin AJ, Fitt S, Williams R, Duncan JS. Fulminant hepatic failure induced by lamotrigine. Br Med J 1995; 311:292.
67. Gram L. Oxcarbazepine. In: Engel J, Pedley TA (editors): Epilepsy: a comprehensive textbook. New York: Lippincott-Raven; 1997. pp. 1541-1546.
68. McKee PJ, Blacklaw J, Forrest G, Gillham R, Walker SM, Connelly D, Brodie MJ. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37:27-32.
69. Van-Parys JA, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine on a named-patient basis. Epilepsy Res 1994; 19:79-85.
70. Bennett GD, Amore BM, Finnell R, Wlodarczyk B, Kalhorn T, Skiles GL, et al. Teratogenicity of carbamazepine-10,11-epoxide and oxcarbazepine in the SWV mouse. J Pharmacol Exp Ther 1996; 279:1237-1242.
71. Sachdeo RC, Leroy RF, Krauss GL, Drake ME, Green PM, Leppik I, et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. Arch Neurol 1997, 54:595-601.
72. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997; 48:1025-1023.
73. Gustavson LE, Boellner SW, Granneman GR, Qian JX, Guenther HJ, el-Shourbagy T, Sommerville KW. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997; 48:1032-1037.
74. Reife RA, Pledger GW. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997; 38 (Suppl 1):S31-S33. This is the pooled analysis of all placebo-controlled trials of topiramate in patients with partial epilepsy.
75. Biton V. Preliminary open-label experience with topiramate in primary generalized seizures. Epilepsia 1997; 38 (Suppl 1):S42-S44.
76. Sander JW. Practical aspects of the use of topiramate in patients with epilepsy. Epilepsia 1997; 38 (Suppl 1):S56-S58.
77. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996; 37:774-780.
78. Rosenfeld WE, Liao S, Kramer LD, Anderson G, Palmer M, Levy RH, Nayak RK. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997; 38:324-333.
79. Rosenfeld WE, Doose DR, Walker S, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38:317-323. This is an elegant study that demonstrates the interaction between the contraceptive pill and topiramate.
80. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26:389-395. This study clearly demonstrates that vigabatrin is better than hydrocortisone as a first-choice treatment for infantile spasms due to tuberous sclerosis.
81. Rundfeldt C, Loscher W. Development of tolerance to the anticonvulsant effect of vigabatrin in amydala-kindled rats. Eur J Pharmacol 1992; 213:351-366.
82. Seino M, Ito T. Zonisamide. In: Engel J, Pedley TA (editors): Epilepsy: a comprehensive textbook. New York: Lippincott-Raven; 1997. pp. 1619-1626.
83. Akaho R. The effects of antiepileptic drugs on cognition in normal volunteers. Psychiatry Clin Neurosci 1996; 50:61-69.
84. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37:1242-1244.
85. Takaya M, Terry WJ, Naritoku DK. Vagus nerve stimulation induces a sustained anticonvulsant effect. Epilepsia 1996; 37:1111-1116.
86. Salinsky MC, Uthman BM, Ristanovic RK, Wernicke JF, Tarver WB. Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group. i 1996; 53:1176-1180.